Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers September 30, 2014
Pharmacy Choice - News - Generic Drugs - September 30, 2014

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 39     Next >>     Go To Page:

9/30/14 - EPIRUS Updates on Positive 58 Week Follow up Data for BOW015 [Professional Services Close - Up]
Biopharmaceuticals has reported positive 58 week follow up data from its BOW015 efficacy and safety trial comparing BOW015, a biosimilar infliximab, to Remicade. This data suggests the patients can safely be started and maintained on BOW015 and that patients can be safely switched from Remicade to BOW015, "said Michael Wyand, DVM, PhD, senior vice
9/30/14 - FDAnews Announces Impact of GDUFA Performance Metrics on ANDA Approval Times: Opportunities, Risks and Practical Considerations Webinar, Oct. 15, 2014
For generic drugmakers, Oct. 1 is crunch time, the date after which all ANDA amendment and prior-approval supplement applications must meet new performance goals under the Generic Drug User Fee Amendments of 2012.. Attendees will discover concrete examples that illustrate what ANDA sponsors can expect and must prepare for. Here's a point-by-point s
9/29/14 - EPIRUS BIOPHARMACEUTICALS, INC. FILES (8-K) Disclosing Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
On September 24, 2014, Epirus Switzerland GmbH, a wholly-owned subsidiary of EPIRUS Biopharmaceuticals, Inc., entered into an Exclusive License and Collaboration Agreement with Livzon Mabpharm Inc. for the global development and commercialization of certain antibodies or related biological compounds, including the Company's BOW015, a biosimilar...
9/29/14 - Ethical Pharmaceuticals Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020
Transparency Market Research includes new market research report "Positron Emission Tomography Market" to its huge collection of research reports.Albany, NY 09/29/2014 Ethical pharmaceuticals or prescription drugs are those licensed drugs that are regulated by various legislations to require a written medical prescription before it can be pro
9/29/14 - Gilead Announces Generic Licensing Agreements to Increase Access to Hepatitis C Treatments in Developing Countries
By a News Reporter-Staff News Editor at Pharma Business Week Gilead Sciences, Inc. announced that the company has signed non-exclusive licensing agreements with seven India- based generic pharmaceutical manufacturers to expand access to its chronic hepatitis C medicines in developing countries. The agreements allow the companies- Cadila Healthcar
9/29/14 - Mylan Commences Phase III Clinical Trials for its Generic Version of Advair Diskus and Insulin Analog to Lantus
By a News Reporter-Staff News Editor at Clinical Trials Week Mylan Inc., one of the world's leading global pharmaceutical companies, announced it is initiating Phase III clinical trials for its generic version of GlaxoSmithKline's Advair Diskus and its insulin analog to Sanofi's Lantus . We look forward to providing patients with access to h
9/29/14 - TPI's QLF Completes GMP site inspection by CFDA
Tianyin Pharmaceutical Co., Inc., a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine, branded generics and active pharmaceutical ingredients, today announce d that its Qionglai Facility has successfully completed the official site visit by the China Food& Drug Administration's for its.
9/29/14 - Why the same drug may have different prices [Daily Monitor, The (Uganda)]
Recently, Patrick Kasozi, went to a pharmacy in Ntinda to buy ampiclox, an anti-biotic drug made of ampicillin and cloxacillin. One was from India and the other from United Kingdom. However, Fred Ssekyana, the public relations officer at the National Drug Authority, says generic drugs are as effective as branded ones.
9/28/14 - Research and Markets Offers Report: Analyzing the Generic Drugs Sector of the US Pharmaceutical Industry - 2014 [Professional Services Close - Up]
Research and Markets has announced the addition of the "Analyzing the Generic Drugs Sector of the US Pharmaceutical Industry- 2014" report to its offerings. In a release, Research and Markets noted that report highlights include:. Being a major section of the report, Promoting Generic Drug Competition in the US Market covers topics such as issues w
9/27/14 - GPhA Supports DEA Prescription Drug Take-Back Day
Generic Pharmaceutical Association issued the following news release:. The Generic Pharmaceutical Association is proud to support the U.S. Drug Enforcement Administration's ninth National Prescription Drug Take-Back Day, taking place Saturday, September 27 at local take-back sites across America. "Take-Back Day reminds millions of Americans,...
The Medicines Patents Pool, which is backed by the United Nations, has signed six sub-licences with companies Aurobindo, Cipla, Desano, Emcure, Hetero Labs and Laurus Labs. The sub-licences will allow these companies to make generic anti-AIDS medicine Tenofovir Alafenamide for 112 developing countries. TAF is a novel investigational medicine from..
9/26/14 - Abbott Completes Acquisition of CFR Pharmaceuticals; Announces Results of Tender Offer for CFR Shares
Acquisition enhances Abbott's position in Latin America, more than doubling its branded generics pharmaceutical sales and presence in the fast-growing region. ABBOTT PARK, Illinois, Sept. 26, 2014/ PRNewswire/ Abbott has acquired control of CFR Pharmaceuticals, more than doubling its Latin American branded generics pharmaceutical presence and f
9/26/14 - Abbott Labs Completes Acquisition Of Chile's CFR Pharma In $2.9 Bln Deal
NORTH CHICAGO- Diversified healthcare company Abbott Laboratories said Friday it has acquired control of Chile- based drugmaker CFR Pharmaceuticals S.A.. The company noted that the acquisition of CFR Pharma in a $2.9 billion deal will more than double its branded generics pharmaceutical presence in Latin America and expand its presence in fast-grow
9/26/14 - EPIRUS Reports Positive 58 Week Follow up Data for BOW015 [Health & Beauty Close - Up]
Biopharmaceuticals has reported positive 58 week follow up data from its BOW015 efficacy and safety trial comparing BOW015, a biosimilar infliximab, to Remicade. This data suggests the patients can safely be started and maintained on BOW015 and that patients can be safely switched from Remicade to BOW015, "said Michael Wyand, DVM, PhD, senior vice
9/26/14 - Par Pharmaceutical Resumes Shipment of Generic Precedex Injection
By a News Reporter-Staff News Editor at Health& Medicine Week Par Pharmaceutical Companies, Inc. announced that it has resumed shipping dexmedetomidine hydrochloride injection, EQ 100 mcg base/mL, the generic version of Hospira's Precedex Injection. Par immediately resumed shipping after a U.S. District Court lifted a temporary restraining order
9/25/14 - Actavis Confirms Generic Butrans Patent Challenge
Purdue Pharma L.P. filed suit against Actavis on September 24, 2014 in the U.S. District Court for the District of Delaware seeking to prevent Actavis from commercializing its ANDA product prior to the expiration of certain U.S. The lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Actavis'
9/25/14 - CMEA Portfolio Company Neos Therapeutics Acquires Rights to Generic Tussionex and Settles Litigation with Shire
San Francisco, CA 09/25/2014 CMEA Capital portfolio company Neos Therapeutics, Inc., a specialty pharmaceutical company with highly differentiated proprietary oral drug delivery technologies and a late-stage pipeline of innovative controlled release products for ADHD, announced that it has acquired all commercialization rights to its Hydrocod
9/25/14 - Coherus BioSciences Appoints Mary Szela to Board of Directors [Global Data Point]
"Coherus has established a highly effective biosimilar development platform to gain regulatory approval of these complex biologics, and shares my personal desire to increase access to essential therapeutics to patients around the world," said Ms. Szela. " Ms. Szela joined Melinta Therapeutics as director in January 2013 and was named Chief Executiv
9/25/14 - IGI Laboratories, Inc. Acquires Eighteen Former Products From AstraZeneca
IGI Laboratories, Inc., a New Jersey based specialty generic pharmaceutical company, today announced it has acquired the regulatory rights and related documents and records for 18 drug products from AstraZeneca, 17 of which were marketed. Jason Grenfell-Gardner, President and CEO of IGI Laboratories, commented, "This acquisition begins the next c
9/25/14 - Lannett Gets FDA Approval of Oxycodone Hydrochloride Oral Solution [Professional Services Close - Up]
Lannett Company recently reported that it has received approval from the U.S. Food and Drug Administration of its abbreviated new drug application for oxycodone hydrochloride oral solution USP, 100 mg per 5 mL. "Oxycodone Hydrochloride Oral Solution USP, 100 mg per 5 mL, is an important and long awaited addition to our pain management franchise an
9/25/14 - Leading UAE Pharmaceutical Company Sponsors Ethiopia Healthcare Summit
Julphar's investments in Ethiopia help meet local demand on affordable high quality medicines and reduce reliance on imports. "Julphar's support for the Healthcare Summit comes at a time where the UAE and Ethiopia are strengthening their trading ties. Last year Julphar has established its first manufacturing plant outside the UAE, in Addis Ababa,
9/25/14 - Pfenex Adds New Board Member
Pfenex Inc., a clinical-stage biotechnology company engaged in the development of high-value and difficult to manufacture proteins including biosimilar therapeutics, today announced the appointment of Robin D. Campbell, Ph.D., to the company's board of directors. "Robin Campbell brings extraordinary medical and pharmaceutical operating experienc
9/25/14 - Pharmaceutical Packaging Market Forecast 2014-2024
Opportunities for Leading Companies in OTC& Non-OTC Pharmaceuticals. Pharmaceutical packaging- new study showing you trends and predicted revenues Given the active nature of pharmaceutical ingredients, proper pharmaceutical packaging is essential to maintain the integrity of the product. The ageing population, expanding generics market, increasing.
9/25/14 - Research and Markets Offers Report: Biosimilars - Biosimilars on the Cusp of a New Era [Professional Services Close - Up]
Research and Markets has added "Biosimilars- Biosimilars on the Cusp of a New Era" report to its offerings. In a release, Research and Markets noted that report highlights include:. In order to keep up with the pace of change in the marketplace, regulatory agencies have been developing updated guidance around the development and approval of biosimi
9/24/14 - : FDA Affirms Permissive Comparative Claim Policies, While Establishing Foundation for Restrictive Guidance [TendersInfo (India)]
At the same time, published social science research from the Office of Prescription of Drug Promotion suggests that FDA policies will become more restrictive in the future. For example, FDA could seek to limit comparative claims to generic products that have been found interchangeable with, or at least comparable to, their innovator counterparts.
Articles(s): 1 - 25 of 39     Next >>     Go To Page:

© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


The Diversion of Controlled Substances and the Law
This lesson is supported by:
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement